"We are honored that CIRM has recognized the promise of P-BCMA-101 as an immunotherapy for patients with multiple myeloma and is contributing to the advancement of this program in Phase 1 clinical development," said Eric Ostertag, M.D., Ph.D., chief executive officer of Poseida. "P-BCMA-101 is elegantly designed with several key characteristics, including an exceptionally high concentration of stem cell memory T-cells which has the potential to significantly improve durability of response to treatment."
The P-BMCA-101 product candidate is a CAR-T immunotherapy designed to supercharge a patient's own T cells to safely and effectively eliminate tumor cells carrying B cell maturation antigen (BCMA), which is expressed on essentially all multiple myeloma cells. P-BCMA-101 modifies a patient's T cells using a non-viral gene delivery system called piggyBac™, which enables several desirable features, including:
"Poseida is developing a promising next generation CAR-T cell therapy which includes many of the desirable attributes of emerging CAR-T cell therapies into a single treatment," said Maria Millan, M.D., President and CEO of CIRM. "CIRM is pleased to support Poseida in the development of this novel CAR-T therapy which represents a much-needed solution for multiple myeloma."
Additional information about this Phase 1 clinical study of P-BCMA-101 is available at www.clinicaltrials.gov using identifier: NCT03288493
About Poseida Therapeutics Inc.
Poseida Therapeutics is translating best-in-class gene therapy technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for cancer, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida's lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene therapy technologies, including the piggyBac™ DNA Modification System, XTN™ TALEN and NextGEN™ CRISPR site-specific nucleases, and Footprint-Free™ Gene Editing (FFGE). For more information, visit www.poseida.com.
Corporate Communications Contact:
To read more Press Release articles, click here.